NEW YORK (GenomeWeb News) – Luminex reported after the close of the market Monday that its first quarter 2014 revenues grew 6 percent, driven by an 18 percent spike in assay sales, as well as an increase in consumables sales.

Austin, Texas-based Luminex reported total revenues of $56.6 million for the three months ended March 31, compared to revenues of $53.2 million for the first quarter of 2013. It beat the consensus Wall Street estimate for revenues of $55.3 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.